JP2002538771A - Ｈｉｖ−１の融合及び付着の相乗的阻害、そのための組成物および抗体 - Google Patents

Ｈｉｖ−１の融合及び付着の相乗的阻害、そのための組成物および抗体

Info

Publication number
JP2002538771A
JP2002538771A JP2000587730A JP2000587730A JP2002538771A JP 2002538771 A JP2002538771 A JP 2002538771A JP 2000587730 A JP2000587730 A JP 2000587730A JP 2000587730 A JP2000587730 A JP 2000587730A JP 2002538771 A JP2002538771 A JP 2002538771A
Authority
JP
Japan
Prior art keywords
composition
hiv
compounds
antibody
ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2000587730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002538771A5 (https=
Inventor
オルソン、ウイリアム・シー
マドン、ポール・ジェイ
Original Assignee
プロジェニクス・ファーマスーティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロジェニクス・ファーマスーティカルズ・インコーポレイテッド filed Critical プロジェニクス・ファーマスーティカルズ・インコーポレイテッド
Publication of JP2002538771A publication Critical patent/JP2002538771A/ja
Publication of JP2002538771A5 publication Critical patent/JP2002538771A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000587730A 1998-12-16 1999-12-16 Ｈｉｖ−１の融合及び付着の相乗的阻害、そのための組成物および抗体 Ceased JP2002538771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21279398A 1998-12-16 1998-12-16
US11253298P 1998-12-16 1998-12-16
US09/212,793 1998-12-16
US60/112,532 1998-12-16
PCT/US1999/030345 WO2000035409A2 (en) 1998-12-16 1999-12-16 Hiv-i fusion inhibition compounds

Publications (2)

Publication Number Publication Date
JP2002538771A true JP2002538771A (ja) 2002-11-19
JP2002538771A5 JP2002538771A5 (https=) 2007-02-15

Family

ID=26810060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000587730A Ceased JP2002538771A (ja) 1998-12-16 1999-12-16 Ｈｉｖ−１の融合及び付着の相乗的阻害、そのための組成物および抗体

Country Status (13)

Country Link
EP (2) EP1144006B1 (https=)
JP (1) JP2002538771A (https=)
AT (1) ATE375802T1 (https=)
AU (3) AU773175B2 (https=)
CA (1) CA2355607A1 (https=)
CY (1) CY1107858T1 (https=)
DE (1) DE69937369T2 (https=)
DK (1) DK1144006T3 (https=)
ES (1) ES2296416T3 (https=)
HK (1) HK1041207B (https=)
MX (1) MXPA01006097A (https=)
PT (1) PT1144006E (https=)
WO (1) WO2000035409A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847452B1 (en) 1995-06-07 2009-04-01 Progenics Pharmaceuticals, Inc. Monoclonal antibody for inhibiting hiv-1 envelope glycoprotein mediated membrane fusion
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US20060078537A1 (en) * 2001-12-21 2006-04-13 Matthias Mack Mono-and dual chemokine/cytokine constructs
DE60324664D1 (de) * 2002-02-22 2008-12-24 Pdl Biopharma Inc Anti-ccr5 antikörper
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP2009525301A (ja) * 2006-01-30 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー Ｈｉｖを処置するための相乗的組成物
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1998018826A2 (en) * 1996-10-28 1998-05-07 Leukosite, Inc. Anti-ccr5 antibodies and methods of use therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU735460B2 (en) * 1996-06-14 2001-07-12 Aaron Diamond Aids Research Center, The Uses of a chemokine receptor for inhibiting HIV-1 infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1998018826A2 (en) * 1996-10-28 1998-05-07 Leukosite, Inc. Anti-ccr5 antibodies and methods of use therefor

Also Published As

Publication number Publication date
AU2004205165A1 (en) 2004-09-16
EP2088158A2 (en) 2009-08-12
CA2355607A1 (en) 2000-06-22
AU2004205164A1 (en) 2004-09-16
PT1144006E (pt) 2007-12-11
EP1144006A4 (en) 2004-11-24
DE69937369T2 (de) 2008-07-24
AU2199600A (en) 2000-07-03
HK1041207B (en) 2007-12-28
EP1144006A2 (en) 2001-10-17
ATE375802T1 (de) 2007-11-15
DK1144006T3 (da) 2007-11-26
DE69937369D1 (de) 2007-11-29
HK1041207A1 (en) 2002-07-05
WO2000035409A3 (en) 2000-09-14
AU773175B2 (en) 2004-05-20
ES2296416T3 (es) 2008-04-16
CY1107858T1 (el) 2013-06-19
EP1144006B1 (en) 2007-10-17
MXPA01006097A (es) 2002-04-15
WO2000035409A2 (en) 2000-06-22
EP2088158A3 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
US7060273B2 (en) Methods for inhibiting HIV-1 infection
US7666419B2 (en) Anti-CCR5 antibody
CA2940685C (en) Anti-egfrviii antibodies and uses thereof
US6548636B2 (en) Sulfated CCR5 peptides for HIV-1 infection
US20070274986A1 (en) Compositions comprising anti-CCR5 antibody
JP2002538771A (ja) Ｈｉｖ−１の融合及び付着の相乗的阻害、そのための組成物および抗体
US20020146415A1 (en) Methods for inhibiting HIV-1 infection
AU2003217674B2 (en) Anti-CCR5 antibody
US20080015348A1 (en) Nucleic acids encoding polypeptides of anti-CCR5 antibodies
AU2007254697B2 (en) Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto-I
EP1900376A2 (en) Synergistic inhibition of HIV-1 fusion and attachment, compsitions and antobodies thereto
HK1133020A (en) Monoclonal antibody against the ccr5 chemokine receptor
HK1117065A (en) Synergistic inhibition of hiv-1 fusion and attachment, compsitions and antobodies thereto
HK1232899B (en) Anti-egfrviii antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100205

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100427

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20100824